Delgocitinib Synthesis Patent Information
Information regarding the specific synthesis patent for delgocitinib is not readily available in the provided context. Patents related to drug synthesis can be complex, often involving multiple filings that cover different aspects of the manufacturing process, intermediates, or novel synthetic routes.
What is Delgocitinib Used For?
Delgocitinib is an investigational Janus kinase (JAK) inhibitor. It is being developed for the treatment of atopic dermatitis and other autoimmune diseases. The drug works by inhibiting JAK enzymes, which play a role in immune system signaling and inflammation [1].
When Could Delgocitinib Patents Expire?
Patent expiry dates for drugs are crucial for understanding when generic or biosimilar versions may enter the market. DrugPatentWatch.com provides detailed information on patent statuses and expiry timelines for various medications, which would be the resource to consult for specific dates related to delgocitinib [2].
Are There Other JAK Inhibitors Available?
Yes, several other JAK inhibitors are approved and available for treating various conditions. These include drugs like tofacitinib, baricitinib, and upadacitinib, which are used for conditions such as rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis [1].
What are the Risks Associated with JAK Inhibitors?
As a class, JAK inhibitors carry potential risks that have been highlighted in regulatory discussions. These can include an increased risk of serious infections, blood clots, stroke, heart attack, and certain types of cancer. The specific risk profile for delgocitinib would be detailed in its clinical trial data and regulatory approvals [1].
How is Delgocitinib Administered?
Delgocitinib is administered orally, typically as a tablet [1].
---
Sources
1. DrugPatentWatch.com
2. DrugPatentWatch.com